For more information, visit and Forward-Looking StatementsĬertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of the Company’s agreement with Solis and future prospects for the Company’s technology platforms and products. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
PROFOUND AI ICAD SOFTWARE
ICAD’s Breast Health Solutions suite also includes ProFound AI for 2D Mammography, ProFound AI Risk, the world’s first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram,3 and software to evaluate breast density. In a reader study published in Radiology: Artificial Intelligence, ProFound AI for DBT Version 2.0 was shown to offer clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent.2 We’re excited to put this technology to work – on behalf of our patients – across our national network of facilities.” “From a patient perspective, improved specificity and sensitivity means that we can minimize the anxiety caused by false positives and recalls, without compromising cancer detection rates. “Late last year we made the decision to go enterprise-wide with ProFound AI,” said Alexander Sardiña, MD, Chief Medical Officer for Solis Mammography. ProFound AI Version 3.0 was developed using over five million images from 30,000 cases, including almost 8,000 biopsy-proven cancers, and validated on approximately one million images from 3,500 cases that included 1,200 biopsy-proven cancers. Case Scores, which are assigned to each case by the algorithm, help clinicians to gain a sense of case complexity, which may be useful for prioritizing the reading work list. The Certainty of Finding scores help radiologists by aiding in clinical decision making. Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent its confidence that a detection or case is malignant. It became the first 3D tomosynthesis software using artificial intelligence (AI) to be FDA cleared in December 2018.īuilt with the latest in deep-learning technology, ProFound AI for DBT rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities. ProFound AI for DBT is a high-performance, deep-learning, workflow solution trained to detect malignant soft tissue densities and calcifications. To increase sensitivity while simultaneously improving specificity is a huge performance achievement.” “Improvements in specificity, which correlates with reductions in false positives, typically come at the expense of sensitivity and cancer detection scores.
Our third generation AI solution for DBT may afford physicians the ability to interpret an increasing amount of data in DBT cases and analyze each image to detect malignant lesions more efficiently and with even greater precision,” said Michael Klein, Chairman and CEO of iCAD. ICAD's Xoft Brain IORT Demonstrates Significant Improvement in Overal.“The FDA Clearance of ProFound AI Version 3.0 is yet another milestone that positions iCAD and our technology as vanguards in the cancer detection realm. ICAD to Host Educational Roundtable to Help Clinicians and Facilities. ICAD Launches Revolutionary Short-term Personalized Risk Assessment S. + Unveils Next Generation Technologies at Journees Francophones de. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Tuesday, November 9. ICAD to Report Third Quarter 2021 Financial Results on Tuesday, November 9
0 kommentar(er)
